Literature DB >> 19073162

Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis.

Anupam Bishayee1, Neetika Dhir.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers and lethal diseases. In view of the limited treatment and a grave prognosis of liver cancer, preventive control has been emphasized. Resveratrol, a polyphenol found in grape skins, peanuts, berries and red wine, has been shown to possess potent growth inhibitory effects against various human cancer cells. Although resveratrol has been found to exhibit chemopreventive actions in experimentally induced skin, breast, colon and esophagus rodent tumors, chemopreventive potential of this dietary constituent has not been explored well against experimental liver cancer. We evaluated the inhibitory effect of resveratrol using a two-stage model of rat hepatocarcinogenesis in Sprague-Dawley rats. Initiation was performed by a single intraperitoneal injection of diethylnitrosamine (DENA, 200 mg/kg), followed by promotion with phenobarbital (0.05%) in drinking water. The rats had free access to food supplemented with resveratrol equivalent to 50, 100 or 300 mg/kg body weight/day. Resveratrol treatment was started 4 weeks prior to the initiation and continued for 20 weeks. Resveratrol dose-dependently reduced the incidence, total number and multiplicity of visible hepatocyte nodules. Mean nodular volume and nodular volume as percentage of liver volume were also inhibited upon resveratrol treatment. Histopathological examination of liver tissue confirmed the protective effect of resveratrol. Immunohistochemical detection of cell proliferation and assay of apoptosis indicated a decrease in cell proliferation and increase of apoptotic cells in the livers of resveratrol-supplemented rats. Resveratrol also induced the expression of pro-apoptotic protein Bax, reduced anti-apoptotic Bcl-2 expression, with a concurrent increase in Bax/Bcl-2 ratio with respect to DENA control. The present study provides evidence, for the first time, that resveratrol exerts a significant chemopreventive effect on DENA-initiated hepatocarcinogenesis through inhibition of cell proliferation and induction of apoptosis. Resveratrol-induced apoptogenic signal during rat liver carcinogenesis may be mediated through the downregulation of Bcl-2 and upregulation of Bax expression. Due to a favorable toxicity profile, resveratrol can potentially be developed as a chemopreventive drug against human HCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073162     DOI: 10.1016/j.cbi.2008.11.015

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  52 in total

1.  Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity.

Authors:  W D Johnson; R L Morrissey; A L Usborne; I Kapetanovic; J A Crowell; M Muzzio; D L McCormick
Journal:  Food Chem Toxicol       Date:  2011-09-10       Impact factor: 6.023

2.  Geraniol modulates cell proliferation, apoptosis, inflammation, and angiogenesis during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis.

Authors:  Veerasamy Vinothkumar; Shanmugam Manoharan; Ganapathy Sindhu; Madhavan Ramados Nirmal; Venkatesan Vetrichelvi
Journal:  Mol Cell Biochem       Date:  2012-06-23       Impact factor: 3.396

Review 3.  The role and place of medicinal plants in the strategies for disease prevention.

Authors:  Abayomi Sofowora; Eyitope Ogunbodede; Adedeji Onayade
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-08-12

Review 4.  Chemopreventive strategies in hepatocellular carcinoma.

Authors:  Siddharth Singh; Preet Paul Singh; Lewis R Roberts; William Sanchez
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-13       Impact factor: 46.802

5.  Apoptotic effects of dipyrido [3,2-a:2',3'-c] phenazine (dppz) Au(III) complex against diethylnitrosamine/phenobarbital induced experimental hepatocarcinogenesis in rats.

Authors:  Neslihan Tekin; Mehmet C Ustuner; Fahrettin Akyuz; Cansu S Ozbayer; Ozlem Aydın; Kadriye Benkli; Dilek Burukoglu; Irfan Degirmenci; Hilmi Ozden
Journal:  Mol Biol Rep       Date:  2014-04-23       Impact factor: 2.316

6.  Chemoprevention against hepatocellular carcinoma.

Authors:  Jun-Ichi Okano; Yuki Fujise; Ryo Abe; Ryu Imamoto; Yoshikazu Murawaki
Journal:  Clin J Gastroenterol       Date:  2011-06-04

Review 7.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

Review 8.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

Review 9.  Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

Review 10.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.